Rapport d’analyse de la taille, de la part et des tendances du marché mondial du cancer des voies biliaires – Aperçu de l’industrie et prévisions jusqu’en 2031

Analyse du marché du cancer des voies biliaires

Ces dernières années, le marché du cancer des voies biliaires devrait connaître une croissance rapide au cours de la période de prévision. Le carcinome des voies biliaires est une maladie rare qui peut affecter à la fois l'intérieur et l'extérieur du foie (intrahépatique et extrahépatique) (extrahépatique). Le nombre de cas signalés est plus faible. Cependant, le taux global de développement semble être plus élevé, car de nombreux patients atteints de cancer sont diagnostiqués à tort avec d'autres cancers. Selon l'American Cancer Society, cette maladie est particulièrement courante dans les pays d'Asie du Sud-Est en raison d'une infection parasitaire, qui peut développer un cancer dans la région des voies biliaires du corps humain.

Taille du marché du cancer des voies biliaires

La taille du marché mondial du cancer des voies biliaires a été évaluée à 214,25 millions USD en 2023 et devrait atteindre 382,12 millions USD d'ici 2031, avec un TCAC de 7,50 % au cours de la période de prévision de 2024 à 2031.

Portée du rapport et segmentation du marché       

Bile Duct Cancer Market Dynamics

Drivers

• Increased Exposure to Toxic Chemicals

Increased exposure to toxic chemicals for printing and other applications is having a negative impact on industrial workers. As a result of these considerations, bile duct cancer treatment is expected to grow in popularity across the healthcare industry.     

• Increasing Investment For Healthcare Infrastructure

Another significant factor influencing the growth rate of bile duct cancer market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the bile duct cancer market. Other factors such as rise in prevalence rate of bile duct cancer will positively impact the bile duct cancer market's growth rate. Additionally, high disposable income and rising demand for advanced treatment and innovative solutions will expand the bile duct cancer market. Along with this, increasing prevalence of liver fluke will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the bile duct cancer market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the bile duct cancer market during the forecast period.

Restraints/Challenges 

On the other hand, the high cost associated with the treatment of bile duct cancer will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the bile duct cancer market. Additionally, the impact of COVID-19 on supply chain and the dearth of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2024-2031.

This bile duct cancer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bile duct cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to the World Health Organization, cancer kills almost 8.3 million people. Bile duct cancer is an uncommon type of cancer, with only about 2,500 new cases detected each year in the United States. Cholangiocarcinoma, commonly known as bile duct cancer, mainly affects persons over the age of 50, however, it can strike anyone at any age.

Bile duct cancer market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Bile Duct Cancer Market

In collaboration with governments throughout the world, pharmaceutical and biotech businesses are working to combat the COVID-19 pandemic, from vaccine development to logistics planning. There are around 115 vaccine candidates and 155 compounds in the Research and innovation pipeline. In addition, frequently used medications notably hydroxychloroquine have seen a tremendous increase for COVID-19 treatment. Due to the increased demand for these treatments, producers of COVID-19 management medications have a lot of potential because several wealthy countries are running out of them. Therefore, due to the need for vaccines and therapeutic medications for COVID-19, the pharmaceutical and biotechnology industries are anticipated to rise significantly in the future. As a result, the bile duct cancer medication industry is projected to have a considerable impact.

Bile Duct Cancer Market Scope

The bile duct cancer market is segmented on the basis of product, disease indication, distribution channel and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• 5-fluorouracil (5-FU)
• Gemcitabine
• Cisplatin
• Capecitabine
• Oxaliplatin

Application

• Hospitals
• Clinics
• Others

Disease Indication

• Intrahepatic Bile Duct Cancer
• Extrahepatic Bile Duct Cancer
  • Perihilar Bile Duct Cancer
  • Distal Extrahepatic Bile Duct Cancer

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Bile Duct Cancer Market Regional Analysis

The bile duct cancer market is analysed and market size insights and trends are provided by country, product, disease indication, distribution channel and application as referenced above.

The countries covered in the bile duct cancer market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the bile duct cancer market because of the prevalence of bile cancer and the growing number of ongoing research activities in this region. 

Asia-Pacific is expected to grow during the forecast period due to rising number of awareness programs and increase in public and private investment in this region. Also, rapid and easy production approval process will enhance the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Bile Duct Cancer Market Share

The Bile duct cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bile duct cancer market.

Bile Duct Cancer Market Leaders Operating in the Market Are:

• Johnson & Johnson Private Limited (US)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Jerusalem)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• AbbVie Inc. (US)
• Novartis AG (Switzerland)
• Fresenius Kabi AG (Germany)
• Eli Lilly and Company (US)
• F. Hoffmann-La Roche SA (Suisse)
• Intercept Pharmaceuticals (États-Unis)
• Kyowa Kirin Co., Ltd. (Japon)
• Delcath Systems, Inc. (États-Unis)
• Accord Healthcare (États-Unis)
• CONMED Corporation (États-Unis)
• Boston Scientific Corporation (États-Unis)
• Bayer AG (Allemagne)
• Société Bristol-Myers Squibb (États-Unis)
• Merck & Co., Inc. (États-Unis)

Dernières évolutions sur le marché du cancer des voies biliaires

• En avril 2020, la Food and Drug Administration américaine a approuvé le premier traitement ciblé pour les patients atteints de cholangiocarcinome appelé Pemazyre (pemigatinib). L'approbation de Pemazyre était basée sur les résultats d'un essai clinique dans lequel 107 patients atteints de cholangiocarcinome localement avancé ou métastatique qui avaient déjà reçu un traitement et présentaient une fusion ou un réarrangement du gène FGFR2 ont été inclus.

SKU-18026